Seladelpar: a comprehensive review of its clinical efficacy and safety in the treatment of primary biliary cholangitis

Ajay Kumar Shukla; Saurav Misra

doi:10.1515/jbcpp-2024-0124

Artikel

Seladelpar: a comprehensive review of its clinical efficacy and safety in the treatment of primary biliary cholangitis

Ajay Kumar Shukla und Saurav Misra

Veröffentlicht/Copyright: 11. August 2025

Veröffentlicht von

Veröffentlichen auch Sie bei De Gruyter Brill

Manuskript einreichen Informationen für Autor*innen Erkunden Sie dieses Fachgebiet

Aus der Zeitschrift Journal of Basic and Clinical Physiology and Pharmacology Band 36 Heft 5

Abstract

Primary biliary cholangitis (PBC) is a chronic liver disease leading to liver damage and potentially death. The first-line treatment is ursodeoxycholic acid (UDCA), but some patients do not respond well. Obeticholic acid (OCA) is a second-line treatment option. Fenofibrate (a predominantly PPAR-α agonist) and bezafibrate (a pan-PPAR agonist) are currently used in clinical practice as anticholestatic agents to improve serum biochemistry in PBC. Seladelpar, a peroxisome proliferator-activated receptor-delta (PPARδ) agonist, has demonstrated potent anti-cholestatic effects in clinical studies. The aim of this analysis was to summarise the data available on efficacy and safety of seladelpar for the treatment of primary biliary cholangitis (PBC). We conducted a search in PubMed, Embase and Web of Science for studies on seladelpar until June 1, 2024. The analysis included review articles, randomized controlled trials, cohort studies and case-control studies. Seladelpar is a once daily oral, potent and selective PPAR-δ agonist. Activation of PPAR-δ on hepatocytes and cholangiocytes improves cholestasis by downregulating the rate-limiting enzyme, CYP 7A1, used for bile synthesis, as well as reducing cholesterol synthesis and dietary absorption, leading to a reduction in bile acid pools. In this review, we have summarised the preclinical and clinical data on seladelpar. There is a need for additional phase III studies to provide sufficient clinical evidence for the efficacy and safety of this investigational drug, as current evidence is limited to phase III studies and does not yet prove its worth in a larger population.

Keywords: primary biliary cholangitis (PBC); peroxisome proliferator-activated receptors (PPARs); seladelpar

Corresponding author: Dr. Saurav Misra, MBBS, MD, Assistant Professor, Department of Pharmacology, Kalpana Chawla Government Medical College, Karnal, Haryana, India, E-mail: saurav181087@gmail.com

Research ethics: The local Institutional Review Board deemed the study exempt from review.
Informed consent: Not applicable.
Author contributions: AKS – Concept, Idea, Data collection, data analysis, Writing the article, final editing. SM – Concept, Idea, Data collection, data analysis, Writing the article, final editing, Submission.
Use of Large Language Models, AI and Machine Learning Tools: None used.
Conflict of interest: Authors state no conflict of interest.
Research funding: None.
Data availability: Yes.

References

1. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67:145–72. https://doi.org/10.1016/j.jhep.2017.03.022.Suche in Google Scholar PubMed

2. Lleo, A, Wang, GQ, Gershwin, ME, Hirschfield, GM. Primary biliary cholangitis. Lancet 2020;396:1915–26. https://doi.org/10.1016/s0140-6736(20)31607-x.Suche in Google Scholar

3. Pandit, S, Samant, H. Primary biliary cholangitis. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2024.Suche in Google Scholar

4. Colapietro, F, Gershwin, ME, Lleo, A. PPAR agonists for the treatment of primary biliary cholangitis: old and new tales. J Transl Autoimmun 2023;6:100188. https://doi.org/10.1016/j.jtauto.2023.100188.Suche in Google Scholar PubMed PubMed Central

5. Lleo, A, Marzorati, S, Anaya, JM, Gershwin, ME. Primary biliary cholangitis: a comprehensive overview. Hepatol Int 2017;11:485–99. https://doi.org/10.1007/s12072-017-9830-1.Suche in Google Scholar PubMed

6. McGee, EE, Castro, FA, Engels, EA, Freedman, ND, Pfeiffer, RM, Nogueira, L, et al.. Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults. Int J Cancer 2019;144:707–17. https://doi.org/10.1002/ijc.31835.Suche in Google Scholar PubMed PubMed Central

7. Parés, A, Albillos, A, Andrade, RJ, Berenguer, M, Crespo, J, Romero-Gómez, M, et al.. Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. Rev Esp Enferm Dig 2018;110:641–9. https://doi.org/10.17235/reed.2018.5665/2018.Suche in Google Scholar PubMed

8. Isayama, H, Tazuma, S, Kokudo, N, Tanaka, A, Tsuyuguchi, T, Nakazawa, T, et al.. PSC guideline committee members: Ministry of Health, Labour and Welfare (Japan) Research Project, The Intractable Hepatobiliary Disease Study Group. Clinical guidelines for primary sclerosing cholangitis 2017. J Gastroenterol 2018;53:1006–34. https://doi.org/10.1007/s00535-018-1484-9.Suche in Google Scholar PubMed PubMed Central

9. Levy, C, Manns, M, Hirschfield, G. New treatment paradigms in primary biliary cholangitis. Clin Gastroenterol Hepatol 2023;21:2076–87. https://doi.org/10.1016/j.cgh.2023.02.005.Suche in Google Scholar PubMed

10. Colapietro, F, Gershwin, ME, Lleo, A. PPAR agonists for the treatment of primary biliary cholangitis: old and new tales. J Transl Autoimmun 2023;6:100188. https://doi.org/10.1016/j.jtauto.2023.100188.Suche in Google Scholar

11. Varga, T, Czimmerer, Z, Nagy, L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta 2011;1812:1007–22. https://doi.org/10.1016/j.bbadis.2011.02.014.Suche in Google Scholar PubMed PubMed Central

12. Claudel, T, Zollner, G, Wagner, M, Trauner, M. Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. Biochim Biophys Acta 2011;1812:867–78. https://doi.org/10.1016/j.bbadis.2010.12.021.Suche in Google Scholar PubMed

13. Ghonem, NS, Assis, DN, Boyer, JL. Fibrates and cholestasis. Hepatology 2015;62:635–43. https://doi.org/10.1002/hep.27744.Suche in Google Scholar PubMed PubMed Central

14. Medscape. [home page in Internet] Seladelpar (Pending FDA Approval). Available from: https://reference.medscape.com/drug/seladelpar-4000434#10 [Cited 11 Jun 2024].Suche in Google Scholar

15. Wetten, A, Emrys, D, Jones, J, Dyson, JK. Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC). Expet Opin Invest Drugs 2022;31:1101–7. https://doi.org/10.1080/13543784.2022.2130750.Suche in Google Scholar PubMed

16. Mao, Z, Martin, R, Steinberg, A, Rohane, P, Nguyen, J, Standen, M, et al.. Pharmacokinetics, safety, and tolerability of seladelpar in subjects with hepatic impairment. In: CymaBay therapeutics. Newark, CA: ETHOS Health Communications in Yardley, USA; 2019.10.1016/S0016-5085(19)40317-XSuche in Google Scholar

17. Kouno, T, Liu, X, Zhao, H, Kisseleva, T, Cable, EE, Schnabl, B. Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway. J Biol Chem 2022;298:102056. https://doi.org/10.1016/j.jbc.2022.102056.Suche in Google Scholar PubMed PubMed Central

18. Bowlus, CL, Galambos, MR, Aspinall, RJ, Hirschfield, GM, Jones, DEJ, Dörffel, Y, et al.. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol 2022;77:353–64. https://doi.org/10.1016/j.jhep.2022.02.033.Suche in Google Scholar PubMed

19. Mayo, M, Vierling, J, Bowlus, C, Levy, C, Hirschfield, GM, Neff, GW, et al.. Long-term safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC): 2-year results from a long-term study. Hepatology 2021;74:71A–3A.Suche in Google Scholar

20. Kremer, AE, Mayo, MJ, Hirschfield, G, Levy, C, Bowlus, CL, Jones, DE, et al.. Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. Liver Int 2022;42:112–23. https://doi.org/10.1111/liv.15039.Suche in Google Scholar PubMed

21. Hirschfield, GM, Beuers, U, Kupcinskas, L, Ott, P, Bergquist, A, Färkkilä, M, et al.. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. J Hepatol 2021;74:321–9. https://doi.org/10.1016/j.jhep.2020.09.011.Suche in Google Scholar PubMed

22. Jones, D, Boudes, PF, Swain, MG, Bowlus, CL, Galambos, MR, Bacon, BR, et al.. Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol 2017;2:716–26. https://doi.org/10.1016/s2468-1253(17)30246-7.Suche in Google Scholar PubMed

23. ENHANCE: safety and efficacy of seladelpar in patients with primary biliary cholangitis-A phase 3, international, randomized, placebo-controlled study. Gastroenterol Hepatol 2021;17:5–6.Suche in Google Scholar

24. Hirschfield, GM, Bowlus, CL, Mayo, MJ, Kremer, AE, Vierling, JM, Kowdley, KV, RESPONSE Study Group, et al.. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med 2024;390:783–94. https://doi.org/10.1056/nejmoa2312100.Suche in Google Scholar PubMed

25. Lin, W, Wang, JX, Liu, YJ. Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis. Syst Rev 2024;13:46. https://doi.org/10.1186/s13643-024-02460-0.Suche in Google Scholar PubMed PubMed Central

Received: 2024-07-18

Accepted: 2025-07-25

Published Online: 2025-08-11

Sie haben derzeit keinen Zugang zu diesem Inhalt.

Artikel in diesem Heft

https://doi.org/10.1515/jbcpp-2024-0124

Schlagwörter für diesen Artikel

primary biliary cholangitis (PBC); peroxisome proliferator-activated receptors (PPARs); seladelpar